Unique ID issued by UMIN | UMIN000006941 |
---|---|
Receipt number | R000008184 |
Scientific Title | A study to evaluate the efficacy of EPA enriched oral nutrition supplement (ONS) and to investigate useful biomarkers for the assessment in advanced gastrointestinal cancer patients |
Date of disclosure of the study information | 2011/12/26 |
Last modified on | 2014/08/18 13:23:04 |
A study to evaluate the efficacy of EPA enriched oral nutrition supplement (ONS) and to investigate useful biomarkers for the assessment in advanced gastrointestinal cancer patients
A study to evaluate the efficacy of EPA enriched oral nutrition supplement (ONS) and to investigate useful biomarkers for the assessment in advanced gastrointestinal cancer patients
A study to evaluate the efficacy of EPA enriched oral nutrition supplement (ONS) and to investigate useful biomarkers for the assessment in advanced gastrointestinal cancer patients
A study to evaluate the efficacy of EPA enriched oral nutrition supplement (ONS) and to investigate useful biomarkers for the assessment in advanced gastrointestinal cancer patients
Japan |
Gastric cancer/Colon cancer
Gastrointestinal surgery |
Malignancy
NO
The aim of this study is to evaluate the efficacy of EPA on nutrition status and quality of life (QOL), and to investigate useful markers for the efficacy of EPA in advanced gastrointestinal cancer patients.
Efficacy
Exploratory
Pragmatic
Phase II
QOL (QOL-ACD) at before and 14days,28days after the administration of EPA
At before and 14days,28days after the administration of EPA
1) Nutrition status
2) Glasgow Prognostic Score (GPS)
3) The expression of cytokines
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Food |
2 packs of an EPA enriched oral nutrition supplement (ONS) per day for 14 days
Not applicable |
Not applicable |
Male and Female
1. GPS:1 or 2
2. Oral intake
3. No abnormality in digestive organs due to endogenous diseases
4. Patients who undergo chemotherapy or who are scheduled to undergo chemotherapy
5. Life expectancy more than 3 months
6. No serious complications
1. Metastatic brain disorder
2. Immune disorder
3. Cardiac disease, liver failure, renal failure, and active disease of small intestine (e.g., Crohn's disease)
4. Gastrointestinal symptoms (e.g., Intestinal obstruction, gastrointestinal bleeding, etc)
5. Allergic to the ingredient (s)
6. Uncontrollable diabetes mellitus
7. Considered inadequate for the inclusion in the study by the physician
20
1st name | |
Middle name | |
Last name | Kouki Kuwabara |
Saitama Medical Center, Saitama Medical University
Department of Digestive Tract and General Surgery
1981 Kamoda, Kawagoe-shi, Saitama, Japan
049-228-3619
47kkuwa@saitama-med.ac.jp
1st name | |
Middle name | |
Last name | Kouki Kuwabara |
Saitama Medical Center, Saitama Medical University
Department of Digestive Tract and General Surgery
1981 Kamoda, Kawagoe-shi, Saitama, Japan
049-228-3619
47kkuwa@saitama-med.ac.jp
Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University
None
Self funding
NO
埼玉医科大学総合医療センター(埼玉県)
2011 | Year | 12 | Month | 26 | Day |
Unpublished
Completed
2011 | Year | 09 | Month | 26 | Day |
2012 | Year | 01 | Month | 01 | Day |
2011 | Year | 12 | Month | 24 | Day |
2014 | Year | 08 | Month | 18 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008184
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |